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A B S T R A C T
Brain is a site of diabetic end-organ damage. Diabetes-associated cognitive dysfunction, referred as "diabetic
encephalopathy" (DE) has been coined for the patients with type 2 diabetes mellitus showing decline in their
cognitive function, especially weak episodic memory, cognitive inflexibility and poor psychomotor performance
leading towards Alzheimer's disease. Current evidence supported that aberrant synapses, energy metabolism
imbalance, advanced glycation end products (AGEs) accumulation and Tau hyperphosphorylation are associated
with cognition deficits induced by diabetes. Oleoylethanolamide (OEA), an endogenous peroxisome proliferator-
activated receptor alpha (PPARα) agonist, has anti-hyperlipidemia, anti-inflammatory and neuroprotective ac-
tivities. However, the effect of OEA on DE is unknown. Therefore, we tested its influence against cognitive
dysfunction in high fat diet and streptozotocin (HFD + STZ)-induced diabetic C57BL/6J and PPARα−-/- mice
using Morris water maze (MWM) test. Neuron staining, dementia markers and neuroplasticity in the hippo-
campus were assessed to evaluate the neuropathological changes. The results showed that chronic OEA treat-
ment significantly lowered hyperglycemia, recovered cognitive performance, reduced dementia markers, and
inhibited hippocampal neuron loss and neuroplasticity impairments in diabetic mice. In contrast, the changes in
MWM performance and neuron loss were not observed in PPARα knockout mice via OEA administration. These
results indicated that OEA may provide a potential alternative therapeutic for DE by activating PPARα signaling.
1. Introduction
Type 2 Diabetes mellitus (T2DM) is one of the most common en-
docrine diseases(Whiting et al., 2011). Without control of glycemic
imbalance, the diabetic patients often accompany with auxiliary com-
plications, such as hepatopathy, retinopathy, and nephropathy
(Lukovits et al., 1999). The central nervous system (CNS) is also very
susceptible to hyperglycemia. Diabetes-related cognitive dysfunction
was first reported in 1922. A series of neurochemical, neurophysiolo-
gical and structural abnormalities in diabetic CNS represent a condition
referred to as ‘diabetic encephalopathy’ (DE) or ‘diabetes-associated
cognitive decline’ (DACD)(Biessels et al., 2002; Mijnhout et al., 2006).
The pathological mechanism of DE includes neurotransmission ob-
struction, synaptic damage and cognition impairment (Awad et al.,
2004; Bhutada et al., 2011). As previous studies showed that the main
pathological markers of Alzheimer's disease (AD), such as the advanced
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glycation end products (AGEs) and Tau hyperphosphorylation, are
implicated in the cognitive impairments of diabetes patients(Gasparotto
et al., 2018). In addition, the pathogenesis of AD is characterized by an
imbalance of cellular energetic metabolism(Steen et al., 2005). Neuron
loss leads to neurotransmitter blockage, synaptic dysfunction and cog-
nitive impairment (Rostami et al., 2013; van den Berg et al., 2010). The
chronic neuronal loss is a common pathological process of diabetes and
AD. Therefore, the relationship between hyperglycemia-induced spatial
memory impairment and neuronal loss has attracted well attention
(Moreno et al., 2004; Pugazhenthi et al., 2017). Peroxisome pro-
liferator-activated receptor α (PPARα) is distributed in all neural cell
types and regulates many physiological processes, such as energy me-
tabolism, neurotransmission, redox homeostasis, autophagy and the cell
cycle(Feige et al., 2006; Heneka and Landreth, 2007; Oveisi et al.,
2004). Recent studies have reported that ligand-activated PPARα in-
hibits the amyloidogenic pathway, Tau hyperphosphorylation, and
neuroinflammation(D'Orio et al., 2018; Santos et al., 2005). However,
the role of PPARα pathway in diabetic encephalopathy has not been
tested in diabetic mice.
Oleoylethanolamide (OEA) is a potent endogenous ligand for
PPARα(Astarita et al., 2006). The protective effects of OEA have been
confirmed in different neuropathologic models(Lombardi et al., 2007;
Sun et al., 2007). Our previous studies have demonstrated that OEA
improved cognitive impairments in cerebral ischemic rats(Yang et al.,
2015) and propane-2-sulfonic acid octadec-9-enyl-amide (N15), a
structural analogue of OEA, played a therapeutic role in high-fat diet
(HFD) and streptozotocin (STZ)-induced T2DM mice(Ren et al., 2018).
Meanwhile, we also found that OEA inhibited ischemic stroke-induced
neuronal cell apoptosis(Yang et al., 2019; Zhou et al., 2017). The anti-
apoptosis effects of OEA were interceded by PPARα pathway, which
stabilizes the resting membrane potential during energy failure to
control the glycemic level in the brain. These findings indicated that
OEA may be considered as a potential therapeutic agent for diabetes
induced encephalopathy syndrome. Accumulating data from clinical
and experimental studies demonstrated that CNS complications being in
both type 1 and type 2 diabetic patients(Kodl and Seaquist, 2008;
Luchsinger, 2012; Meek and Morton, 2012; Zhang et al., 2013). Male
C57BL/6 J treated with HFD and low-dose STZ are considered an ideal
type 2 diabetes animal model(Gilbert et al., 2011). Therefore, in the
present study, we investigated the effects of OEA on cognitive deficits in
HFD + STZ-induced diabetic mice and revealed the underlying me-
chanism.
2. Materials and methods
2.1. Animal experiments
Male C57BL/6 J mice (6–8 weeks old, weighing 20–22 g) were
purchased from Vital River Laboratory Animal Technology Co. Ltd.
(Beijing, China). The PPAR α knockout mice (129S4/SvJae-
Pparatm1Gonz/J) (7–9 weeks old) weighing 20–22 g were from the
Jackson Laboratory (Bar Harbor, ME, USA). Because Sv129 mice are
immunodeficient and have a very low reproductive rate, so we hy-
bridized PPARα and C57BL/6 J mice to further obtain PPARα knockout
mice. All animals were housed in specific pathogen-free (SPF) condi-
tions in a 12/12-h dark/light cycle environment with unrestricted food
and water. All animal studies (including the mouse euthanasia proce-
dure) were performed in compliance with the institutional animal care
regulations and guidelines of Xiamen University and according to
AAALAC and IACUC guidelines. In addition, maximum efforts were
made to minimize the pain and suffering of the animals.
Previous studies indicated that both C57BL/6 J and PPARα
knockout mice can be used to induce diabetic models(Yuan et al.,
2019). T2DM (or DE) was induced in mice with a mix of HFD and low-
dose STZ. After a week of adaptation in the controlled living conditions,
C57BL/6 J mice were randomly divided into five groups (n = 6 for each
group): Normal, DE, DE + OEA-15, DE + OEA-30, or DE + OEA-60.
The PPARα−-/- mice were randomly divided into three groups (n = 6
for each group): Normal, DE, DE + OEA-60. The normal groups were
fed a normal pellet diet and received an intraperitoneal injection of
vehicle throughout the experiment. Other groups were fed an HFD
(30% fat, 20% sugar, 15% protein, 2.5% cholesterol, 1% sodium cholic
acid and 31.5% custom carbohydrate) for 6 weeks and received an
intraperitoneal injection of STZ (40 mg/kg)(Gilbert et al., 2011). Be-
ginning the next day, these mice received a single daily intraperitoneal
injection of OEA (15, 30 or 60mg/kg, respectively, dissolved in Tween-
20/saline: 10/90) or vehicle (Tween-20/saline: 10/90) for 56 days.
2.2. Measurement of the fasting blood glucose, insulin resistance and
lipoprotein
The fasting blood glucose (FBG) levels were measured using a blood
glucose meter (Johnson & Johnson New Brunswick, NJ), once a week,
after 8 h of fasting. The serum insulin level was determined using an
ELISA kit (ALPCO, Windham, NH). Insulin resistance was assessed by
calculating the homeostatic model assessment of insulin resistance
(HOMA-IR), which was previously described(Antunes et al., 2016). The
serum concentrations of total cholesterol (TC), triglyceride (TG), high-
density lipoprotein cholesterol (HDL-C), low-density lipoprotein cho-
lesterol (LDL-C), and the levels of glucose and lactic acid in hippo-
campal tissue were measured by the commercial assay kits (Nanjing
Jiancheng Bioengineering Institute, China) according to the manufac-
turer's instructions.
2.3. Oral glucose tolerance test
Oral glucose tolerance test (OGTT) was performed on C57BL/6J
mice following overnight-fasting period at the 6th week post-treatment.
Mice were administered glucose orally at 2.0 g/kg and tail blood sam-
ples were obtained at 0, 30, 60 and 120min post glucose load using
glucometer.
2.4. Morris water maze test
The Morris water maze (MWM) was performed during days 43–48
and 56 after T2DM(Morris et al., 1982; Peng et al., 2007). The maze
was carried out in a white circular container (120 cm in diameter and
60 cm in height) filled with water at 25 ± 1 °C. A submerged white
circular platform with a diameter of 6 cm was placed 1.0 cm below the
surface of the water. During the maze test, the position of the cues
remained unchanged for spatial orientation.
Phases I. Acquisition: Acquisition training was carried out from day
43–47 after T2DM. The mice received four consecutive daily training
trials in the following 5 days. For each trial, mice were placed in the
water from the same starting position, heading toward the pool wall
with a ceiling time of 60 s. If the mouse found the platform, it was
allowed to remain on it for 10 s. The time to reach the platform (escape
latency) was recorded at the same time. If the mouse failed to find the
platform, it was gently guided onto the platform for 20 s, and the escape
latency was recorded as 60 s.
Phases II. Spatial probe trials: On day 48, the platform was re-
moved, and the mice were given 60 s to swim freely for the spatial
probe trials. The swimming distance, percentage of swimming distance
in the former target or target quadrant, and time spent in the target or
target quadrant were recorded to measure the spatial memory reten-
tion.
Phases III. Memory consolidation test: A probe trial as phase II was
performed on day 56 to measure long-term memory retention.
In brief, the schedule is shown in Supplementary Fig. 1.
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2.5. Western blot analysis
Western blot analyses were performed as previously described.
Briefly, primary antibodies to phospho-Ser214-Tau (1:1000, Abcam),
RAGE (1:1000, Cell Signaling Technology), growth associated protein
43 (GAP43) (1:1000, Cell Signaling Technology), synaptophysin (SYN)
(1:1000, Cell Signaling Technology), recombinant human neuro-
trophin-3 (NT3) (1:1000, Cell Signaling Technology), brain-derived
neurotrophic factor (BDNF) (1:1000, Cell Signaling Technology) and β-
actin (1:10,000; Abcam) at 4 °C overnight. Bound antibodies were in-
cubated with HRP-conjugated goat anti-rabbit secondary antibodies
(ZSGB-BIO, China) at room temperature for 1 h. The protein bands were
visualized and quantified by scanning densitometry using ImageStation
4000 R (Rochester, New York, USA).
2.6. Immunofluorescence and cell counting
Double-labeling of DAPI and neuron was performed using frozen
slides from mice hippocampus as described previously(Zhou et al.,
2017). Briefly, the sections were incubated with mouse monoclonal
anti-NeuN (1:100; Millipore, Billerica, MA, USA) at 4 °C overnight.
After several PBS rinses, sections were incubated with Alexa Flour 594
donkey anti-mouse IgG (1:200; Invitrogen, Carlsbad, CA, USA) for 2 h at
room temperature.
2.7. Statistical analysis
The results were expressed as the mean ± S.E.M. Statistical ana-
lysis was performed using one-way ANOVA and two-way ANOVA with
Tukey's post hoc test for comparisons between two groups followed by
the Student-Newman-Keuls test (Prism 5 for Windows, GraphPad
Software Inc., USA). P values < 0.05 were considered statistically
significant.
3. Result
3.1. OEA suppressed plasma glucose and lipid profiles in diabetic mice
We investigated OEA’ s potential in improving glucose metabolism
in HFD + STZ-induced T2DM mice. OEA administration effectively
reduced plasma glucose concentration after 8 h fasting in HFD + STZ
T2DM mice (Fig. 1 A). After six weeks of OEA administration, OGTT
assay was conducted to measure the influence of OEA on the whole-
body glucose homeostasis, and the results demonstrated that OEA
treatment effectively improves glucose tolerance in three dosage groups
with a dose-dependent therapeutic effect (Fig. 1 B and Supplemental
Fig. 3). OEA also reduced serum insulin and HOMA-IR levels in a dose-
dependent manner (Fig. 1 C and D). chronic treatment with OEA (30
and 60mg/kg) significantly reduced the body weights and water intake
level in diabetic mice (see Supplemental Fig. 2). As shown in Fig. 1 E–H,
the OEA treated mice exhibited less TC, TG, LDL-C and higher HDL-C
levels comparing to the vehicle group, thus indicating the suppressed
hyperlipidemia in T2DM mice.
3.2. OEA attenuated diabetes-induced spatial cognitive deficits
Next, we performed MWM test to examine the effect of OEA on
T2DM induced cognitive dysfunction. On day 47, we found that the
swimming traces of the DE (T2DM) group were distributed around the
edges of the four quadrants (Fig. 2 A). Meanwhile, there was a sig-
nificant difference in escape latency between the diabetic and non-
diabetic control mice. Thus, this model could be used to investigate the
effects of OEA for improving diabetes-induced cognitive ability. Com-
pared to the diabetic mice, the swimming traces of OEA (30 or 60mg/
kg)-treated mice were concentrated in the target zone where the plat-
form had been set (Fig. 2 A). Moreover, OEA-30 or 60-treated group
displayed a shorter latency to find the platform (Fig. 2 B), suggesting
that OEA treatment effectively improved the spatial learning ability
across the 5-day training period.
During the spatial probe trials, in which the platform was removed,
there was no difference in swimming distance among the groups of
mice (Fig. 2 C). Simultaneously, OEA (30 or 60mg/kg) treatment ef-
fectively elevated the percentage of time and journey spent on the
target quadrant (Fig. 2 D and E).
To investigate the effects of OEA on long-term memory recovery, we
tested a probe trial one week after training (Phases III on day 56). The
data showed that OEA (30 or 60mg/kg) treatment markedly reduced
the latency compared with the diabetes group (Fig. 2 F). Similar to the
spatial probe trials, there was no difference in swimming distance
among the groups of mice (Fig. 2 G). After 30 or 60mg/kg OEA
treatment, the percentage of time and journey in the target quadrant
were markedly increased in diabetic mice (Fig. 2 H and I). This finding
indicated that the decline in cognitive function observed in diabetes
mice evidently improved following OEA administration in a dose-de-
pendent manner, especially in long-term memory consolidation.
3.3. OEA decreased hippocampal disturbance of glycometabolism and
phosphorylation of tau induced by diabetes
The proper levels of glucose and lactic acid in hippocampal tissue
have been shown to be essential for learning and memory consolida-
tion. As illustrated in Fig. 3, the concentrations of glucose and lactic
acid were increased in the hippocampus of diabetic mice. However,
OEA-60 treatment significantly reduced the level of glucose compared
with that in the vehicle group (Fig. 3 A). Additionally, the level of lactic
acid was reduced by 30 or 60mg/kg OEA treatment in the hippocampus
of diabetic mice (Fig. 3 B). The results from Fig. 2 show that both 30
and 60mg/kg OEA have protective effects against cognitive impair-
ment, while the effects of OEA at dose of 60mg/kg were more potent
than those of 30mg/kg. Therefore, we chose 60mg/kg to further study
the molecular mechanism. It is clear that hyperglycemia triggers the
production of AGEs, followed by the induction of Tau hyperpho-
sphorylation(Li and Schmidt, 1997; Ramasamy et al., 2008). There was
a significant increase in phospho-Ser214 (p-Ser214) of Tau in the hip-
pocampus of diabetic mice. In contrast, OEA-60mg/kg treatment sig-
nificantly decreased Tau phosphorylation at Ser214 (Fig. 3 C and D).
Moreover, OEA exhibited a robust decrease in RAGE protein expression
(Fig. 3 C and E), suggesting that OEA treatment efficiently improved the
diabetes-induced high levels of AGEs.
3.4. OEA inhibited neuron loss in the hippocampus of diabetic mice
Hippocampal neuron loss is closely related to hippocampus-depen-
dent memory. As shown in Fig. 4, immunostaining for NeuN revealed
that HFD + STZ administration decreased the number of NeuN+ cells
in CA1 hippocampal areas compared with the normal group. In con-
trast, the number of NeuN+ cell in the CA1 hippocampal areas was
robustly increased by OEA-treatment after T2DM. These data suggested
that chronic treatment with OEA significantly inhibited hippocampal
neuron loss induced by HFD + STZ.
3.5. OEA promoted hippocampal neuroplasticity
To further investigate the mechanism by which OEA improves
diabetes-induced cognitive dysfunction, we assessed whether chronic
OEA treatment was able to promote hippocampal neuroplasticity. There
was a significant increase in the protein expression of GAP43 and SYN
in the OEA-treated diabetic mice, suggesting that chronic OEA treat-
ment could enhance hippocampal neuroplasticity after T2DM (Fig. 5
A–C). Additionally, the levels of NT3 and BDNF were markedly upre-
gulated by OEA treatment compared with diabetic mice (Fig. 5 A, D and
E). These data indicated that chronic OEA treatment could enhance
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hippocampal neuroplasticity after T2DM.
3.6. OEA improved neuron loss and spatial cognitive deficits through
PPARα
To confirm whether OEA treatment could reduce neuron loss and
improve cognitive function through PPARα, we further employed
PPARα−-/- mice to induce T2DM. We found that the number of NeuN+
cells was markedly decreased after T2DM in PPARα knockout mice.
Interestingly, the number of NeuN+ cells was not increased after OEA
treatment in CA1 hippocampal areas of diabetic PPARα−-/- mice (Fig. 6
A). However, the NeuN positive cells was increased in C57BL/6 J mice
after OEA treatment (Fig. 4). These data suggested that PPARα was
essential for OEA-improved neuron loss.
We further tested spatial memory using the MWM in PPARα
knockout mice after 56 days of OEA treatment. Consistent with the
C57BL/6 J mice tests, no significant difference was observed in swim-
ming distance among the groups (Fig. 6 D), and diabetic mice had a
poorer memory regarding the platform location. As the latency of dia-
betic PPARα−/− mice to find the platform was significantly increased
compared with the normal group, the percentage of time and journey in
the target quadrant were markedly decreased in diabetic PPARα−/-
mice. However, the roles of OEA in reducing latency time and in-
creasing target quadrant time or journey were not present in diabetic
PPARα−/− mice (Fig. 6 C, E, and F), indicating that OEA alleviated
spatial cognitive deficits in a PPARα-dependent manner.
4. Discussion
Our previous study documented the positive effects of OEA in
stroke-induced cognitive deficits(Yang et al., 2015). Here, we found
that OEA provided protection against diabetes-induced encephalopathy
in HFD+STZ-treated mice. OEA reversed spatial cognitive impairment
and reduced hippocampal hyperglycation after T2DM. Additionally,
OEA exerted a potent anti-DE action by inhibiting neuron loss and
consequently promoting neuroplasticity, and, more importantly, that
the mechanism underlying these effects is dependent on PPARα, par-
ticularly in terms of neuron loss.
Diabetes encephalopathy has a complex pathophysiology.
Epidemiological studies have reported that diabetes is associated with a
greater lethality of stroke and Alzheimer's disease(Lukovits et al.,
1999). Conversely, T2DM increases the risk of atherosclerosis and is
viewed as an autonomous risk factor for stroke(Bruno et al., 2008).
Therefore, diabetes treatment is an important goal for prevention of
DACD morbidity. OEA is well known to induce weight loss and satiety
via activation of PPARα receptor. OEA displays diverse properties and
involves peripheral and/or central mechanisms. The effects of OEA on
receptors such as TRPV1, GPR119 or PPAR-α receptor have been de-
scribed(Sarro-Ramirez et al., 2013). These suggested that OEA may
have anti-atherosclerosis, anti-oxidant, neuroprotective and anti-dia-
betic potential effect. The neuroprotective effect of OEA has been ver-
ified in our previous study(Yang et al., 2015; Zhou et al., 2012, 2017).
In present study, our data showed that OEA exerted a potent anti-in-
sulin resistance action. Moreover, OEA effectively inhibited athero-
sclerotic plaque formation in HFD-fed ApoE−-/- mice(Ma et al., 2015).
The compounds of antihyperglycemics and insulin-sensitizing amelio-
rate memory deficit in the diabetic state. With these backgrounds, the
present study was attempted to examine the roles of OEA in diabetes-
induced cognitive impairment and revealed the underlying mechanism
involving these roles. As shown in the MWM test, OEA considerably
decreased the escape latency during task acquisition of diabetic mice,
implying that OEA treatment adequately improved the spatial learning
abilities of diabetic mice. The probe trials were tested one week after
training, in which OEA was effective in long-term memory recovery
after T2DM, as indicated by the decreased escape latency and increased
time and journey spent in the target quadrant. These data confirmed
that OEA treatment attenuated learning and memory impairment
caused by T2DM.
Hippocampal glucose metabolism is also crucial for the develop-
ment of diabetes, impairing brain functions. In our study, 56 days OEA
administration abolished the enhanced glucose level in the hippo-
campus of mice with T2DM, indicating that OEA could facilitate the
efficiency of hippocampal glucose metabolism in diabetic mice. It is
known that a higher level of glucose can inhibit mitochondrial oxida-
tive phosphorylation, which in turn elevates nonoxidative glucose uti-
lization and then accelerates the production of lactic acid(Belanger
et al., 2011). Indeed, we found that the level of lactic acid was increased
in diabetic mice hippocampus. However, OEA treatment decreased the
Fig. 1. OEA attenuated plasma glucose and lipid profiles in diabetic mice. OEA-treated groups received single daily intraperitoneal injections of OEA (15, 30 or
60 mg/kg), while the normal and HFD + STZ groups were treated with vehicle on a daily basis. Sequential monitoring of blood glucose after 8 h of fasting (A),
glucose tolerance (B), fasting blood insulin (C), HOMA-IR (D), and levels of total cholesterol, total triglycerides, high-density lipoprotein and low-density lipoprotein
in serum (E–H) were measured after 6 weeks of treatment. Values are means ± S.E.M. (n = 6 per group). #P<0.05, ##P < 0.01, ###P < 0.001 vs. the normal
group; *P < 0.05, **P < 0.01, ***P < 0.001 vs. the DE group.
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lactic acid level compared to diabetic mice. Overproduction of lactic
acid may provide an energy substrate for neurons to repay for the
downregulated glucose oxidative phosphorylation. Moreover, an in-
sufficient energy supply induced by the decline of glucose oxidative
phosphorylation would lead to spontaneous apoptosis in neurons and
glial cells. Thus, our results suggested that OEA might play an im-
portant role in the regulation of hippocampal energy metabolism under
high glucose conditions.
Recent evidence has indicated that T2DM is one of the major risk
factors for AD development (Yarchoan and Arnold, 2014). Consistent
with previous work(Yoon et al., 2010), the level of hyperpho-
sphorylated Tau was markedly increased in the hippocampus of T2DM
mice, but this change was reversed by OEA treatment. It has been
shown that hyperglycemia promotes Tau hyperphosphorylation in the
hippocampus, finally resulting in the dysfunction of neural cells
(Gasparotto et al., 2015). Under physiological conditions, RAGE is low
Fig. 2. OEA ameliorated T2DM-induced spatial cognitive deficits. A representative swimming trace in the spatial probe trials for each group (A). The
escape latency (B and F) and swimming distance (C and G) in the hidden platform trials. The time spent (D and H) and the distance (E and I) in the target
quadrant. Values are means ± S.E.M. (n= 6 per group). #P < 0.05, ##P < 0.01, ###P < 0.001 vs. the normal group; *P < 0.05, **P < 0.01, ***P < 0.001 vs.
the DE group.
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expressed in most tissues. However, RAGE expression is significantly
elevated in chronic diseases. Here we found that OEA treatment ex-
hibited a robust decrease in the expression of RAGE protein, suggesting
that OEA treatment efficiently improved diabetes-induced high levels of
AGEs. Tau hyperphosphorylation and RAGE expression were chosen as
markers for evaluating the process of DE. Therefore, our results may
provide insights into the mechanism of OEA in T2DM-induced cognitive
impairments.
It has been observed that learning and memory impairment could
result from neuron loss, and thus we next examined the status of neuron
loss in each group. In the present study, NeuN+ cells number in the CA1
hippocampal areas was greatly enhanced by OEA-treatment after
T2DM. These results suggest that the role of OEA in promoting cogni-
tive function is closely related to enhancing neuron survival in diabetic
mice. Growing preclinical literature provides ample evidences that
diabetes negatively impacts the morphological integrity of the hippo-
campus and reduces hippocampal neurogenesis, in concert with deficits
of other forms of neuroplasticity, may contribute to comorbid cognitive
and mood symptoms in diabetes(Bocchetta et al., 2016). In the present
study, the MWM test and NeuN staining were chosen as methods for
evaluating the effect of OEA on diabetic-associated cognitive defects.
Our data indicated that chronic OEA treatment attenuated damage in
the hippocampus after diabetes-induced encephalopathy.
Neuroplasticity refers to the ability of the brain to adapt, change
and reorganize throughout life. GAP43 is a neuron-specific axon protein
that plays an important role in the regulation of neurite outgrowth,
growth cone guidance and synaptic plasticity(Liu et al., 2005). SYN is a
presynaptic vesicle protein that has a neuroprotective role in
synaptogenesis and synapse functions(Maggio and Vlachos, 2014). Our
results exhibited that OEA treatment markedly increased the expression
of both GAP43 and SYN. It indicated that the role of OEA in improving
diabetes-induced cognitive impairment might have occurred through
enhancing synaptic plasticity. The neurotrophic factors, such as BDNF
and NT3, play critical roles in axonal growth, survival of existing
neurons and plasticity (Zakharenko et al., 2003). Our data showed that
OEA treatment significantly increased the levels of BNDF and NT3.
Therefore, targeting hippocampal neurotrophy and neuroplasticity may
be a potential strategy to reduce the risk of DE and improve DE out-
comes. Considering that neuron loss is closely related to the neuro-
trophy deficiency and neuroplasticity impairment, and that OEA pro-
motes protein levels of GAP43, SYN, BDNF and NT3, thus the
modulatory effects of OEA on neurotrophy and neuroplasticity after DE
may be associated with promoting neuron survival. PPARα is expressed
in high levels in the liver, intestinal mucosa, skeletal muscles, heart,
and brown adipose tissue, where it plays an important role in fatty acid
metabolism, as well as glucose and lipid metabolism(Lagana et al.,
2016; Vitale et al., 2016). PPARα is also highly expressed in the brain
and is considered the crossroads of obesity, diabetes, inflammation and
AD. OEA is a high-closeness agonist of PPARα. Meanwhile, OEA reg-
ulates peripheral lipid metabolism through activation of the nuclear
receptor PPARα(Fan et al., 2014; Fu et al., 2003). Here, we found that
OEA not only regulate blood lipid metabolism in diabetic mice, but also
blood glucose metabolism, especially glucose metabolism in hippo-
campus. In an addition, the data showed that OEA efficiently sup-
pressed neuron loss in CA1 area of diabetic mice hippocampus. In
contrast, OEA failed to normalize the number of NeuN+ cells in PPARα
Fig. 3. Effects of OEA on glucometa-
bolism and Tau hyperpho-
sphorylation in the hippocampus.
The levels of glucose (A) and lactic acid
(B) in the hippocampus were measured
after 56 days of treatment.
Representative Western blot images (C)
and quantitative analysis of protein
expression of p-Tau (D) and RAGE (E)
in the hippocampus of mice after 56
days of treatment. Values are expressed
as percentages compared with the
normal group (set to 100%) and are
represented as means ± S.E.M. (n=6
per group). #P < 0.05, ##P < 0.01,
###P < 0.001 vs. the normal group;
*P < 0.05, **P < 0.01 vs. the DE
group.
Fig. 4. OEA inhibited neuron loss in the hip-
pocampus of diabetic mice. Representative
confocal fluorescence images immunolabeled
with NeuN (red) and DAPI (blue) antibodies (A).
Quantitative analysis of NeuN+/DAPI+ (B).
Values are means ± S.E.M. (n=6 per group).
###P < 0.001 vs. the normal group; **P < 0.01
vs. the DE group. (For interpretation of the re-
ferences to colour in this figure legend, the
reader is referred to the Web version of this ar-
ticle.)
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knockout mice, suggesting that PPARα is not related to regulation en-
ergy metabolism but also to neuroprotection. Meanwhile, our data also
revealed the beneficial roles of OEA in the recovery of cognitive ability.
Interestingly, these beneficial effects were not discovered in the dia-
betic PPARα−-/- mice, indicating that OEA alleviated spatial cognitive
deficits in a PPARα-dependent manner. However, OEA is not only an
endogenous agonist of PPARα, but also TRPV1 and GPR119 receptors.
Therefore, the inhibitory effect of OEA on encephalopathy in diabetic
mice whether is related to TRPV1 and GPR119 receptors need prove by
further experiments.
In conclusion, our data demonstrated that chronic OEA treatment
debilitated diabetes-induced cognitive deficits and regulated hippo-
campal energy metabolism in the diabetic mice. Furthermore, the anti-
diabetic encephalopathy effects of OEA occur via a PPARα-mediated
pathway. Accordingly, OEA may be a promising neuronal protective
agent for diabetic encephalopathy treatment.
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